Brief: Lidds: Liproca Phase IIb Study Results Indicate Cancer Control

Lidds AB

19/05/2020 07:32

May 19 (Reuters) - Lidds AB  LIDDS.ST :
    * REG-LIPROCA PHASE IIB STUDY RESULTS INDICATE CANCER
CONTROL
    * STUDY MET BOTH PRIMARY AND SECONDARY ENDPOINTS
    * MRI DATA SHOWS NO PROGRESSION OF PROSTATE CANCER IN ANY
PATIENTS, AND EVEN REGRESSION IN SOME PATIENTS
    * FINAL DATA FROM LPC-004 STUDY CONFIRMS LIPROCA® DEPOT'S
POTENTIAL AS A SAFE AND EFFECTIVE ANTI-ANDROGEN TREATMENT FOR
PROSTATE CANCER PATIENTS THAT CURRENTLY ARE NOT TREATED BUT KEPT
UNDER 'ACTIVE SURVEILLANCE'

Source text for Eikon:  ID:nGNE2bnfc1 
Further company coverage:  LIDDS.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))